"Ultra-low" doses of the drug rituximab may be enough to keep some patients' rheumatoid arthritis under control for several years, a new, preliminary study suggests.

Researchers found that among 118 patients, low doses of the drug were comparable to standard ones in controlling flare-ups for up to four years.

The findings, the researchers said, suggest that some patients can try low...

An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds.

The medication is called rituximab (Rituxan). It's used to treat a number of conditions, including certain blood cell cancers and the autoimmune condition rheumatoid arthritis.

The new Swiss study found that MS patients tak...